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Purpose: Characterization of dose-response rela-
tionships for psychotropic agents may be difﬁcult to
determine based on results of individual clinical
studies, particularly those with a ﬂexible dose design.
The goal of this pharmacometric analysis was to
characterize the dose-response proﬁle for lurasidone
in patients with bipolar depression.
Methods: The statistical modeling and simulation
analyses reported here were derived from 2 random-
ized, 6-week, double-blind, placebo-controlled,
ﬂexible-dose studies (20–60 mg/d or 80–120 mg/d of
lurasidone as monotherapy or 20–120 mg/d adjunct
to lithium or valproate) in patients with bipolar
depression. Pooled data included 5245 Montgomery-
Åsberg Depression Rating Scale (MADRS) observa-
tions from 825 patients who had received lurasidone
or placebo treatments, with or without lithium or
valproate background medication.
Findings: The time course of placebo effect on the
MADRS score was adequately described by an ex-
ponential asymptotic placebo model. A linear dose-
response model best described the effect of lurasidone.
The net improvement in MADRS score due to lur-
asidone treatment (the drug effect) was signiﬁcant
(P o 0.001), and a positive dose response was
detected. Net drug effect after 6 weeks of treatment
was estimated to be a 6.0-point decrease in MADRS
score per 100 mg of lurasidone. Covariate effects (for
age and lithium or valproate use) were signiﬁcant only
for placebo effect parameters; thus, no dose adjustment
was necessary related to demographic covariates.
Implications: This population dose-response mod-
eling analysis indicates that higher doses of lurasidone
are likely to produce greater therapeutic effects in
patients with bipolar depression. The linear dose
response was consistent for both lurasidone mono-
therapy and adjunctive therapy in patients with bipolar4depression. ClinicalTrials.gov identiﬁers: NCT00868452,
NCT00868699. (Clin Ther. 2016;38:4–15) & 2016 The
Authors. Published by Elsevier HS Journals, Inc.
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model.INTRODUCTION
Bipolar disorder is a serious psychiatric illness char-
acterized by recurring periods of mania, hypomania,
and depression.1 Depressive symptoms dominate the
course of the illness2–4 and are associated with
signiﬁcant impairment in patients’ social and occupa-
tional functioning5–8 and an increased risk of
suicide.9,10
Lurasidone, an atypical antipsychotic agent, is
approved for the treatment of schizophrenia in the
United States and several other countries and as
monotherapy or adjunctive therapy with lithium or
valproate for the treatment of major depressive epi-
sodes associated with bipolar I disorder (bipolar
depression) in the United States and Canada. Lur-
asidone possesses high afﬁnity for dopamine D2,
5-hydroxytryptamine (5-HT)2A, and 5-HT7 receptors
(as an antagonist), moderate afﬁnity for 5-HT1A
receptors (as a partial agonist), and no appreciable
afﬁnity for histamine1 or muscarinic1 receptors.
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randomized, double-blind, placebo-controlled stud-
ies.12,13 The ﬁrst study used 2 ﬁxed-ﬂexible dose
ranges of lurasidone monotherapy (20–60 mg/d or
80–120 mg/d) compared with placebo.12 The second
study evaluated ﬂexibly dosed lurasidone (20–120 mg/d)
compared with placebo as adjunctive treatment with
either lithium or valproate.13
Dose-response relationships for psychotropic
agents may be difﬁcult to determine based on results
of individual clinical studies due to various confounds,
such as study design, variability in attrition, back-
ground medications, and placebo response rates.14,15
Study designs that use ﬂexible dosing, in which doses
are adjusted based on individual response and toler-
ability, are reﬂective of usual clinical practice. How-
ever, a key limitation of the ﬂexible-dose design is the
introduction of selection bias because dose assignment
is not random.16 Therefore, in studies with ﬂexible
dosing, it is difﬁcult to associate treatment response
with a speciﬁc medication dose.
One way to assess and characterize a dose-response
relationship from ﬂexible-dose studies is to use
pharmacokinetic-pharmacodynamic modeling to link
drug exposure to clinical efﬁcacy. A population
exposure-efﬁcacy response model allows for separa-
tion of the effect of time from the overall effect in
ﬂexible-dose studies and provides a longitudinal rep-
resentation of the treatment effect contributed by
placebo, background medication, and study medica-
tion. Modeling and study simulation have been used
to characterize the association between drug exposure
and efﬁcacy in studies of antipsychotic therapy for
schizophrenia.15,17–20
The goal of the present analysis was to characterize
the dose-response proﬁle of lurasidone in the treat-
ment of patients with bipolar depression to inform
clinical dosing decisions and identify patient sub-
groups that might beneﬁt from dose adjustments.
Using data from registration studies of lurasidone in
patients with bipolar depression, a population
exposure-response model was developed to character-
ize Montgomery-Åsberg Depression Rating Scale
(MADRS)21 score change over time as a function of
lurasidone dose. The MADRS is a 10-item, clinician-
rated scale; each item is scored from 0 to 6, and item
scores are summed to obtain an overall score (range,
0–60).21 A MADRS score ofZ20 indicates depression
of moderate or greater severity.22 A dropout modelJanuary 2016was also developed to investigate factors affecting
attrition patterns and to aid in evaluation of the
exposure-efﬁcacy response model. These models
were then used to simulate results from a randomized,
6-week, double-blind, placebo-controlled, ﬁxed-dose
study.PATIENTS AND METHODS
Study Design and Patients
Data were pooled from the 2 pivotal studies of
lurasidone in patients with bipolar depression (study
D1050235 [ClinicalTrials.gov identiﬁer: NCT00868452]
and study D1050236 [ClinicalTrials.gov identi-
ﬁer: NCT00868699]).12,13 The monotherapy study
(D1050236) evaluated ﬁxed ﬂexible dose ranges of
20–60 mg/d or 80–120 mg/d of lurasidone compared
with placebo.12 The adjunctive study (D1050235)
evaluated lurasidone ﬂexible doses between 20 and 120
mg/d compared with placebo as adjunctive treatment
with either lithium or valproate.13 Study procedures were
approved by institutional review boards or ethics
committees at each study site. Studies were conducted
in accordance with the International Conference on
Harmonisation Good Clinical Practice guidelines and
with the ethical principles of the Declaration of Helsinki;
all patients provided written informed consent before
study enrollment.
Study methods are described in detail else-
where12,13 and are summarized brieﬂy here. Both
studies enrolled adult outpatients, 18 to 75 years of
age, who were diagnosed as having bipolar I disorder
and experiencing a major depressive episode (deﬁned
using Diagnostic and Statistical Manual of Mental
Disorders [Fourth Edition, Text Revision] criteria)
with or without rapid cycling and without psychotic
features. To be eligible for enrollment, patients were
required to have a MADRS score Z20 and a Young
Mania Rating Scale score r12. Key exclusion criteria
were a Z25% decrease in MADRS score between
screening and baseline, a score Z4 on MADRS item
10 (suicidal thoughts) at screening or baseline, immi-
nent risk of suicide or injury to self or others, an acute
or unstable medical condition, lack of response to a
Z6-week trial of Z3 antidepressants with or with-
out mood stabilizers during the current depress-
ive episode, and a history of alcohol or substance
abuse (previous 2 months) or dependence (previous
12 months).5
Clinical TherapeuticsThe MADRS was used as the primary measure of
efﬁcacy in the lurasidone phase III trials. The MADRS
assessments were conducted at baseline and weekly
thereafter to study completion or early termination.
Concomitant medications included anticholinergic
agents (eg, benztropine) for movement disorders,
propranolol or amantadine for akathisia, and benzo-
diazepines or sedative-hypnotics (ie, lorazepam, tema-
zepam, zolpidem, or their equivalent) for anxiety or
insomnia. These medications were permitted on an
as-needed basis (not as prophylaxis) but not within
8 hours of any efﬁcacy assessment.
Model Development
Determination of the model structure and testing of
covariates, in the current analysis, used pooled data
from the pivotal studies of lurasidone in patients with
bipolar depression.12,13 In addition, a predictive pop-
ulation pharmacokinetic model for lurasidone based
on data from 17,008 measurable lurasidone serum
concentrations from 2077 individuals (healthy volun-
teers and patients with schizophrenia or bipolar
depression), including inﬂuential covariates, was used
to determine lurasidone exposure in the dose-response
models (data on ﬁle). Source data were processed
using SAS software, version 9 (SAS Institute Inc, Cary,
North Carolina), or Tibco Spotﬁre Sþ software,
version 8.2 (Tibco Software Inc, Palo Alto, Califor-
nia), to create derived datasets for these analyses.
Conceptually, the base dose-response model is
composed of a placebo (nondrug) effect component,
a drug effect component, and residual error. The dose-
response dataset used to generate the base model
included all MADRS observations (excluding screen-
ing and washout) and baseline covariate data from the
lurasidone registration studies. Missing MADRS data
were ﬂagged as missing; no MADRS data were
imputed. In the base model development, functional
forms of the placebo and drug components were ﬁrst
determined. The placebo model component was de-
veloped using data from the placebo group, including
patients in the placebo group receiving lithium or
valproate. The placebo effect component was eval-
uated using the following functions: linear, log-linear,
power, exponential, asymptotic, and exponential
asymptotic with varying rate (based on the Weibull
continuous probability distribution) time effects. After
an adequate ﬁt was achieved, the lurasidone data were
added to the placebo model, and the drug model6component was then evaluated, with adjustment for
the placebo response, using the following functions:
linear, power model, Emax model, and Emax model
with a sigmoidicity parameter (Hill coefﬁcient). Mod-
els were ﬁtted in order of increasing complexity until
the best ﬁt was achieved. Models that included delay
(hysteresis) were assessed if lack of ﬁt was evident.
Equations deﬁning the model are reported in Figure 1.
Exposure measures evaluated as predictors of the
placebo and drug effects (assessed as mean change in
MADRS score) included lurasidone dose, AUC0–24,
concentration at the time of dose before MADRS
measurement (C0), and concentration at 2 hours after
dosing (C2), which served as a surrogate for Cmax.
Pharmacokinetic measures were determined based on
empirical Bayes estimates using the ﬁnal pharmacoki-
netic model conditioned on each patient’s dosing
history and covariates.
Prespeciﬁed covariates that might inﬂuence the
pharmacodynamic response to lurasidone independent
of drug exposure (ie, age, sex, race, weight, psychiatric
history, smoking status, US vs non-US residency,
concurrent medication use, satisfaction with previous
medication[s]) were accounted for in the models. Data
from patients with missing baseline covariate data
were excluded from the covariate analysis datasets;
imputation was unnecessary because missing covariate
data representedo5% of the total data. The MADRS
baseline score was not considered as a covariate
because it was an estimate. A full model was devel-
oped that included all covariate parameter effects
simultaneously. Reduction of the full model to a
working-full model (ie, by removing covariate param-
eters) was considered as instability arose, and this
working-full model was considered only after ﬁrst
ruling out instability associated with the base model,
especially in regard to random effects. A stepwise
procedure for backward elimination was then used to
identify a parsimonious ﬁnal model at α ¼ 0.001.
The dropout pattern may not have been missing
completely at random and was likely to depend on the
MADRS score; therefore, in addition, a model describ-
ing the probability of patient dropout over time was
developed. The pooled dataset for dropout analyses
was constructed to facilitate discrete parametric sur-
vival analysis, with MADRS score as a time-varying
covariate. A time-to-event model was used to illustrate
the association between the MADRS scores (and/or
other covariates) and the time to the dropout event.Volume 38 Number 1
The general form of the exposure-efficacy response model at the patient level was: 
where y = MADRS, f(θ, η) represents the overall patient-specific model (θ denotes fixed effects, η
denotes random effects), fnd represents the non-drug (placebo) model component for placebo 
group (PLCB = 1), fnd’  represents the non-drug model (placebo) component for treatment group 
(PLCB = 0), fd represents the drug model component, (σ ·g) represents the residual error variance 
function (dependent upon η potentially), and ε represents the residual random error (assumed 
normally distributed with mean of 0 and variance of 1). 
A flexible log-linear hazard function was used in the dropout model likelihood equations:
where t is the time variable and the βi are functions of fixed effects and the time-changing 
covariate MADRS – ie, βi(θ, y). When β2
β2
 >0 indicates the  hazard is increasing with time,  
and when      <0 indicates the hazard is decreasing with time. The survival function over an 
arbitrary time interval for this hazard function is:
where the above equation is undefined for β2 = 0. When β2 = 0, the equation results in a constant 
hazard with respect to time (associated with exponential distribution); this model was also 
assessed. Lack of fit was assessed by plotting empiric (nonparametric) estimates of the hazard 
probabilities stratified by key variables that impacted dropout and model predictions. 
MADRS = Montgomery-Åsberg Depression Rating Scale. 
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Figure 1. Model equations.
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dropout model likelihood equations (Figure 1).
Model Evaluation
The predictive performance of the ﬁnal dose-
response model was evaluated using the posterior
predictive check method, which tests to conﬁrm
whether the model can simulate the observed data
conditioned on the study design.23 The ﬁnal evaluation
model was then used to generate 1000 sets of
population parameter values that were used to
simulate datasets from a ﬁxed-dose study, replicatingJanuary 2016design features of the 2 ﬂexibly dosed phase III studies
from which the dose-response model was built (includ-
ing baseline covariates). In these simulated datasets,
placebo and lurasidone at ﬁxed doses of 20, 40, 60, 80,
100, and 120 mg/d were used without titration for
6 weeks; 300 patients were used per treatment arm. The
dropout model was applied to each simulated dataset to
mimic observed dropout patterns. The distribution of
the least-squares mean change in MADRS scores from
baseline predictions at week 6 were computed from the
simulated studies and compared with the least-squares
mean changes for observed study data.7
Clinical TherapeuticsRESULTS
The dose-response dataset included 5245 MADRS
observations from 825 patients with bipolar depres-
sion who had received lurasidone or placebo (with or
without lithium or valproate background medica-
tion) in the registration studies. The mean (SD)
observed MADRS score at baseline was 30.5 (5.0)
in the monotherapy study and 30.6 (5.0) in the
adjunctive study. The Table summarizes base-
line demographic and clinical characteristics that
served as covariates in model development and
evaluation. The covariate distribution was largely
similar among the studies. The mean age was 41.6
years, 47% of patients were women, 64% were
white, 42% were smokers, and 37% resided in the
United States.Table. Demographic and baseline clinical characteristics
Characteristic
Monotherapy
(n ¼ 48
Age, mean (SD), y 41.5 (12.
Female, No. (%) 209 (43
Race, No. (%)
White 320 (66
Black 67 (13
Other 98 (20
Weight, mean (SD), kg 101 (50
Age at onset of illness, mean (SD),
y
27.6 (11.
Duration of illness, mean (SD), y 13.9 (10
No. of hospitalizations, mean (SD) 1.1 (1.4
Current smoker, No. (%) 200 (41.
US resident, No. (%) 195 (40
Lithium or valproate use, No. (%)
None 485 (10
Lithium 0 (0)
Valproate 0 (0)
Other concomitant medication use,
No. (%)
110 (22
MSQ score, mean (SD)* 3.3 (1.1
Study dropouts, No. (%) 110 (22
*The global satisfaction item from the Medication Satisfaction
higher scores indicating greater satisfaction, was used to as
disorder.
8Exposure-Efficacy Response Model
Placebo Effect
The time proﬁle of MADRS score for placebo was
adequately described using an exponential asymptotic
model. Plots of placebo-effect model ﬁt relative to
observed data are shown in Figure 2. The model
estimate of the baseline MADRS score for placebo was
30.7 points; the MADRS score decreased throughout 6
weeks of treatment to the estimated maximum decrease of
13.2 points without background medication, 16.2 points
with lithium, and 15.3 points with valproate. The placebo
model–estimated MADRS decrease had an onset rate of
0.0419 day–1 (half-life of 16.5 days), indicating that 50%
of the placebo effect was estimated to have occurred in
2.5 weeks and that 12 weeks was estimated to be required
to reach 95% of the maximum effect.(covariates).
Study
5)
Adjunctive Study
(n ¼ 340)
Overall
(N ¼ 825)
3) 41.7 (11.6) 41.6 (12.1)
.1) 178 (52.4) 387 (46.9)
.0) 210 (61.8) 530 (64.2)
.8) 41 (12.1) 108 (13.1)
.3) 89 (26.2) 187 (22.7)
.3) 100 (49.4) 100 (49.9)
2) 28.8 (10.8) 28.1 (11.0)
.9) 13.0 (11.1) 13.5 (11.0)
) 1.2 (1.5) 1.1 (1.5)
2) 142 (41.8) 342 (41.5)
.2) 110 (32.4) 305 (37.0)
0) 0 (0) 485 (58.8)
164 (48.2) 164 (19.9)
176 (51.8) 176 (21.3)
.7) 91 (26.8) 201 (24.4)
) 3.6 (1.2) 3.5 (1.2)
.7) 58 (17.1) 168 (20.4)
Questionnaire (MSQ), which was scored from 1 to 7, with
sess satisfaction with previous medication(s) for bipolar
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Figure 2. Change in Montgomery-A˚sberg Depression Rating Scale (MADRS) score in patients receiving
placebo: model predictions compared with observed values by study. IPRED ¼ model predictions
for the individual using the fixed-effect estimates evaluated at the empirical Bayes predictions of the
patient-specific random variables (etas); Obs ¼ observed.
S. Chapel et al.Drug Effect
To characterize the potential dose-response rela-
tionship for lurasidone, data from lurasidone treat-
ment were added to the placebo model structure. The
time proﬁle of MADRS scores on either placebo or
lurasidone was adequately described using a linear
dose-response relationship built on an exponential
asymptotic placebo model (see Supplemental Table I
in the online version at http://dx.doi.org/10.1016/
j.clinthera.2015.11.013). A net improvement in
MADRS score due to lurasidone treatment (the drug
effect) was signiﬁcant (P o 0.001), and a positive
dose-response relationship was detected.
The mean net drug effect at the week 6 end point
(after adjusting for placebo and lithium or valproate
treatment effect) was estimated to be a 6.0-point
decrease from baseline in MADRS score per 100 mg
of lurasidone (3.5, 3.8, 4.5, 5.1, 6.0, and 6.5 points
in MADRS scores for 20, 40, 60, 80, 100, and
120 mg, respectively). The drug effect onset rate was
0.263 day–1 (half-life of 2.6 days), indicating that
50% of the drug effect was estimated to have occurredJanuary 2016after 3 days and that approximately 2 weeks was
estimated to be required to reach 95% of the max-
imum effect. Thus, the drug model, which accounts
for the net effect (placebo-corrected) of lurasidone,
found that the pharmacokinetic/pharmacodynamic
relationship for the drug effect reached steady state
at week 2, with the net drug effect remaining steady
thereafter. In the ﬁnal exposure-efﬁcacy response
model, lurasidone dose with drug effect onset rate
was a better predictor of MADRS response than the
pharmacokinetic exposure measures evaluated (ie,
serum AUC0–24, C0, and C2).Covariate Effects
A full model was constructed assessing the effect of
prespeciﬁed covariates on baseline MADRS, maxi-
mum placebo effect, and drug effect; it revealed that
only age and lithium or valproate use had signiﬁcant
effects and that these covariate effects were statisti-
cally signiﬁcant only on placebo effect parameters and
not on the drug effect slope.9
Clinical TherapeuticsDropout Events and Dropout Model
Across studies, the overall observed dropout rate
was 20.4%, with the monotherapy study exhibiting a
larger proportion of dropouts (22.7%) than the
adjunctive therapy study (17.1%). In the monother-
apy study, the dropout rate was slightly higher with
lurasidone (23.2%) than with placebo (21.6%), and
the rate for the 80–120 mg/d of lurasidone group
(24.1%) was slightly higher relative to the rate for the
20–60 mg/d of lurasidone group (22.4%). In the
adjunctive therapy study, the dropout rate was some-
what higher for the patients assigned to the lurasidone
and lithium or valproate treatment group (19.0%)
compared with that for the placebo and lithium or
valproate group (14.9%).0 1 2 3 4 5 6
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Figure 3. Goodness of fit for dropout model prediction
study participation over time by dose of lura
model compared the observed Kaplan-Meier c
Meier curves (gray lines).
10Plots of dropout model ﬁt relative to observed data
indicate that the Kaplan-Meier curves simulated by the
dropout model were consistent with the observed
dropout rate (Figure 3). In the dropout model
constructed using data from both studies, a log-linear
hazard was determined to be the best predictor, and
the ﬁnal dropout model indicated that greater attrition
rates were associated with higher MADRS scores,
supporting the assumption of dropout pattern being
missing at random. This model also suggested that
attrition rates decreased as lurasidone dose increased.
Simulation
The posterior predictive check of the distri-
butions of weekly mean change in MADRS score for0 1 2 3 4 5 6
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s versus observed probability of patients’ continued
sidone. The visual predictive check for the dropout
urve (solid black line) with 1000 simulated Kaplan-
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S. Chapel et al.model-generated versus observed data revealed good
agreement, indicating that the ﬁnal dose-response model
had adequate predictive performance (Figure 4). Thus,
the ﬁnal lurasidone dose-response model, developed from
ﬂexible-dose study data, was used to simulate results from
a ﬁxed-dose study. The ﬁnal dropout model estimates (see
Supplemental Table II in the online version at http://
dx.doi.org/10.1016/j.clinthera.2015.11.013) were used to
create the dropout pattern for each simulated study. The0 1 2 3 4 5 6 0 1 2
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Figure 4. Predictive distribution of the observed mean
observed mean scores. MADRS ¼ Montgome
January 2016simulation results reﬂect a dose-dependent effect for
lurasidone in patients with bipolar depression in a ﬁxed-
dose study setting (Figure 5), indicating that a higher dose
of lurasidone, given as either monotherapy or adjunctive
therapy, is likely to produce a larger drug effect.
DISCUSSION
To our knowledge, this is the ﬁrst published popula-
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Figure 5. Simulated dose–MADRS response of
lurasidone at week 6 for fixed-dose
designs. Mean change in MADRS
from baseline, placebo corrected,
median with 90% prediction interval.
MADRS ¼ Montgomery-A˚sberg
Depression Rating Scale.
Clinical Therapeuticstreatment studies in patients with bipolar depression.
The dose-response modeling and study simulation
procedures used in this analysis separated the drug
effect from the placebo effect and also accounted for
varying patterns of attrition. The ﬁnal dose-efﬁcacy
response model successfully described the dose-
response curve for lurasidone across the therapeutic
dose range for patients with bipolar depression
(20–120 mg/d). A linear dose-dependent effect was
found, indicating that higher doses of lurasidone are
associated with greater improvement in depressive
symptom severity in patients with bipolar depression,
relative to lower doses. The dose-response relationship
was consistent for lurasidone as both monotherapy
and adjunctive therapy with lithium or valproate. The
estimated net drug effect (after adjusting for placebo
and lithium or valproate treatment effect) was a 6.0-
point decrease in MADRS score per 100 mg of
lurasidone after 6 weeks of treatment. We note that
a 2-point decrease in MADRS score is regarded as a
clinically relevant drug-placebo difference in patients
with depression.24 In addition, this analysis revealed
that rates of attrition were lower at higher doses of
lurasidone. These results suggest that dose increase12could be an effective strategy for patients with bipolar
depression who initially have a suboptimal treatment
response to lurasidone.
Measures of drug exposure evaluated in this study
included lurasidone pharmacokinetic parameters
(ie, Cmax and AUC) and the medication dose. Of these
measures, lurasidone dose (with drug effect onset rate)
was the best predictor of improvement in depressive
symptoms. Covariate effects were not signiﬁcant
on drug-effect parameters, indicating that dose
adjustment of lurasidone is not necessary based on
demographic parameters in patients with bipolar
depression.
We note that the ﬁndings of the modeling analysis
reported here are in contrast to the observed results of
the monotherapy study,12 in which the higher dose
range of lurasidone (80–120 mg/d) did not provide
additional efﬁcacy on average compared with the
lower dose range (20–60 mg/d). There are several
possible explanations for this discrepancy.
First, the ﬂexible-dose nature of the lurasidone
monotherapy study may have obscured the ability to
detect a dose-response relationship based on observed
data. Patients within ﬂexible dose groups who are
more responsive to the study medication are likely to
receive doses that are lower in the available range,
whereas those who do not have satisfactory symptom
improvement may be titrated to higher doses. There-
fore, dose selection in such ﬂexible dose studies may,
in large part, be determined by treatment response;
the timing of the response can also be correlated with
dose assignment. In addition, in studies of ﬁxed
length similar to this study, shorter duration of
exposure to higher doses compared with lower doses
(due to the need for titration) is likely to further
complicate evaluation of response to higher doses.
These factors, taken together, reduce the likelihood of
observing a dose-response relationship at a given
time point (ie, study end point) in a ﬂexible trial
setting.
Second, the lurasidone monotherapy study was
powered to detect separation of each dose range from
placebo; it was not powered to detect separation of
each dose level from placebo or separation between
the dose levels. The number of patients estimated to be
required to separate each dose level from placebo
would considerably increase the sample size used in
this study; separation between dose levels would
require an even larger study. Thus, because of a lackVolume 38 Number 1
S. Chapel et al.of sample size (ie, adequate power), dose-response
relationships in this study may have been difﬁcult to
detect based on observed data.
Third, variability in dropout pattern is another
potential source of bias in characterizing dose-
response relationships in clinical studies, particularly
when the rate of attrition is associated with medica-
tion dose.16 In the lurasidone monotherapy study,
the dropout rate was slightly higher in the 80- to
120-mg/d dose group (24.1%) compared with the
20- to 60-mg/d group (22.4%). The dropout models
derived from the present analysis found that treatment
discontinuation may be associated with insufﬁcient
efﬁcacy (as indicated by higher MADRS scores at
dropout), which is consistent with ﬁndings from a
modeling analysis of a ﬂexible-dose, unipolar de-
pression study.25 Although the modeling did not
speciﬁcally account for the effect of adverse events,
the relatively low dropout rates due to adverse events
(6%–7%)12,13 reduced their potential effect on this
analysis.
We note that the magnitude of the drug effect
(treatment effect minus placebo effect) may be larger
in ﬂexible-dose compared with ﬁxed-dose studies, as
was observed in an analysis of 51 antidepressant
studies.26 In that analysis, the likelihood that active
medication would produce results superior to placebo
on study outcome measures was 59.6% in ﬂexible-
dose studies compared with 31.4% in ﬁxed-dose
studies, a difference that was explained, in part, by a
smaller placebo effect observed in ﬂexible-dose
(29.3% symptom reduction) versus ﬁxed-dose
(35.8% symptom reduction) studies.26 These ﬁnd-
ings indicate a potential advantage of ﬂexible-dose
studies in providing greater sensitivity for identifying a
minimum efﬁcacious dose. In the ﬂexible-dose lurasi-
done studies,12,13 62% of 56 patients who received a
maximum dose of 20 mg/d had a450% reduction in
MADRS score, suggesting that 20 mg/d of lurasidone
could serve as the minimum efﬁcacious dose in
patients with bipolar depression.
Several limitations of this analysis should be con-
sidered. The ﬂexible dose nature of the studies on
which the dose-response analysis was based suggests
that patients were not exposed to each dose within
each study for the same length of time. This discrep-
ancy could have limited the ability of the model to
reﬂect the true effects of each dose, particularly higher
doses, on treatment response. Relatively high placeboJanuary 2016response, variability in treatment response, and sam-
ple size limitations in clinical trials of central nervous
system disorders, including the trials that underlie this
analysis, can impair the sensitivity of the model to
fully describe dose-response effects. The safety proﬁle
of lurasidone across the therapeutic dose range should
be considered, in addition to these dose-response
ﬁndings, when individual treatment decisions are
made.
In summary, this dose-response modeling analysis
supports a positive, linear dose-response relationship
for 20–120 mg/d of lurasidone in the treatment of
patients with bipolar depression as both monotherapy
and adjunctive therapy to lithium or valproate, with
no required dose adjustment related to demographic
characteristics. Approximately 2 weeks was estimated
to be required to reach 95% of the maximum
lurasidone drug effect. These ﬁndings indicate the
value of modeling and study simulation as supple-
ments to the standard analytic methods used in
individual clinical studies.
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